10 results
8-K
EX-99.1
NUVL
Nuvalent Inc - Ordinary Shares
9 May 24
Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2024 Financial Results
6:37am
, cash equivalents and marketable securities to be sufficient to fund its current operating plan into 2027.
R&D Expenses: Research and development (R&D) expenses
8-K
EX-99.1
NUVL
Nuvalent Inc - Ordinary Shares
27 Feb 24
Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones and Reports Fourth Quarter and Full Year 2023 Financial Results
6:38am
to be sufficient to fund its current operating plan into 2027.
R&D Expenses: Research and development (R&D) expenses were $35.6 million
8-K
EX-99.1
NUVL
Nuvalent Inc - Ordinary Shares
14 Nov 23
Nuvalent Highlights Corporate and Pipeline Achievements and Reports Third Quarter
6:45am
of approximately $282 million, are expected to extend the company's operating runway into 2027.
R&D Expenses: Research and development (R&D) expenses
8-K
EX-99.1
NUVL
Nuvalent Inc - Ordinary Shares
10 Aug 23
Nuvalent Highlights Pipeline Progress and Reports Second Quarter 2023 Financial Results
6:45am
and marketable securities are expected to be sufficient to fund its current operating plan into the second half of 2025.
R&D Expenses: Research … and development (R&D) expenses were $25.9 million for the second quarter of 2023.
G&A Expenses: General and administrative (G&A) expenses were $8.1 million
8-K
EX-99.1
NUVL
Nuvalent Inc - Ordinary Shares
11 May 23
Nuvalent Announces Anticipated Timing of Preliminary Phase 1 Dose-Escalation Data for NVL-655 and Reports First Quarter 2023 Financial Results
6:39am
of 2025.
R&D Expenses: Research and development (R&D) expenses were $22.1 million for the first quarter of 2023.
G&A Expenses: General and administrative
8-K
EX-99.1
4y8 tpy7oy2ypgc
10 Nov 22
Nuvalent Reviews Corporate and Pipeline Achievements and Reports Third Quarter 2022 Financial Results
6:37am
8-K
EX-99.1
f9sqz0aojj4plthzycvp
10 Aug 22
Nuvalent Highlights Execution Across Pipeline of Novel Kinase Inhibitors and Reports Second Quarter 2022 Financial Results
12:00am
8-K
EX-99.1
wt4 z855vjd
12 May 22
Nuvalent Highlights Pipeline and Business Progress and Reports First Quarter 2022 Financial Results
6:45am
8-K
EX-99.1
drwy fh1b1
29 Mar 22
Nuvalent Reports Pipeline and Business Progress and Fourth Quarter and Full Year 2021 Financial Results
6:58am
8-K
EX-99.1
nr1k2 671phtw8e
10 Nov 21
Nuvalent Reports Pipeline Progress and Third Quarter 2021 Financial Results
6:44am
- Prev
- 1
- Next